--- title: "RAPT Therapeutics Completes Acquisition and Transitions to Private Ownership" type: "News" locale: "en" url: "https://longbridge.com/en/news/277639919.md" description: "RAPT Therapeutics has completed a merger under Delaware law, transitioning to private ownership without a shareholder vote. The company has notified Nasdaq for the halt and delisting of its shares, implemented governance changes, and replaced its board and executives. The latest analyst rating for RAPT stock is a Hold with a $58.00 price target, reflecting weak financial performance but strong technical momentum. RAPT focuses on developing therapies for immune and inflammatory diseases and cancer, previously listed on Nasdaq with a market cap of $1.61B." datetime: "2026-03-03T14:37:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277639919.md) - [en](https://longbridge.com/en/news/277639919.md) - [zh-HK](https://longbridge.com/zh-HK/news/277639919.md) --- # RAPT Therapeutics Completes Acquisition and Transitions to Private Ownership ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The latest update is out from RAPT Therapeutics ( (RAPT) ). On March 3, 2026, RAPT Therapeutics completed a merger under Delaware law that did not require a shareholder vote, resulting in all validly tendered shares being accepted for payment and the company becoming a direct wholly owned subsidiary of the acquiring parent. In connection with the closing, RAPT notified Nasdaq of the transaction, requested the halt and delisting of its shares and subsequent deregistration with the SEC, and implemented sweeping governance changes, including the resignation of the prior board, replacement of all incumbent officers with executives from the purchaser, and the adoption of amended and restated charter documents, effectively transitioning RAPT from a publicly traded entity to a privately held subsidiary under new control. The most recent analyst rating on (RAPT) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page. **Spark’s Take on RAPT Stock** According to Spark, TipRanks’ AI Analyst, RAPT is a Neutral. The score is held back primarily by weak financial performance (no revenue, large losses, and heavy cash burn). Offsetting that, the stock shows strong upward technical momentum and, most importantly, a definitive cash acquisition agreement at $58/share materially supports the near-term investment profile despite remaining deal-closure conditions. To see Spark’s full report on RAPT stock, click here. **More about RAPT Therapeutics** RAPT Therapeutics operates in the biopharmaceutical industry, historically focusing on the discovery and development of oral small molecule therapies targeting immune and inflammatory diseases and cancer. The company’s shares were previously listed on Nasdaq, giving it access to public equity markets and a broad base of institutional and retail investors. **Average Trading Volume:** 2,649,246 **Technical Sentiment Signal:** Buy **Current Market Cap:** $1.61B For a thorough assessment of RAPT stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [RAPT.US](https://longbridge.com/en/quote/RAPT.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) ## Related News & Research - [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md) - [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md) - [IT Sector Accounts for Nearly One Third of U.S. Securities Litigation Risk in 1H 2026](https://longbridge.com/en/news/294507902.md) - [Generic drug sector seeks policy fixes after Trump tariff threat](https://longbridge.com/en/news/293501714.md) - [Has the bull market shifted to biotech stocks?](https://longbridge.com/en/news/293077044.md)